Acción CTX CRESCITA THERAPEUTICS INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Crescita Therapeutics Inc.

Acciones

CTX

CA2258471028

Mercado cerrado - Toronto S.E.
Otros sitios de cotización
 18:59:15 09/05/2024 		Varia. Cinco días. Varia. 1 de enero.
0,435 CAD 0,00 % Gráfico intradía de Crescita Therapeutics Inc. +1,16 % -11,22 %
08/05 Crescita Therapeutics amplía sus pérdidas en el primer trimestre y aumenta sus ingresos MT
08/05 Crescita Therapeutics Inc. informa de los resultados del primer trimestre finalizado el 31 de marzo de 2024 CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Crescita Therapeutics Q1 Loss Widens, Revenue Rises
Crescita Therapeutics Brief: Q1 Revenue was $4.996 Million
Crescita Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Crescita Reports First Quarter 2024 Results
Crescita Therapeutics Reports Q4 Net Loss of $0.01 Per Share
Tranche Update on Crescita Therapeutics Inc.'s Equity Buyback Plan announced on August 29, 2023.
Crescita Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Crescita Therapeutics Brief: Q4 EPS Basic and Diluted Loss $0.01
Crescita Reports Q4 and Fiscal 2023 Results
Crescita Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
North American Morning Briefing : Stock Futures -2-
Tranche Update on Crescita Therapeutics Inc.'s Equity Buyback Plan announced on August 29, 2023.
Crescita Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Crescita Reports Third Quarter 2023 Results
Crescita Therapeutics Obtains TSX Approval for Normal Course Issuer Bid
Crescita Therapeutics Brief: Announced Approval of Normal Course Issuer Bid
Crescita Therapeutics Announces Approval of Normal Course Issuer Bid
Crescita Therapeutics Inc. announces an Equity Buyback for 1,821,616 shares, representing 8.94% of its issued share capital.
Crescita Therapeutics Inc. authorizes a Buyback Plan.
- Crescita Therapeutics Brief: Q2 Revenue $5.162 Million; Ending cash was $10,226, down $49 for the quarter
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción CTX
  4. Noticias Crescita Therapeutics Inc.
  5. Otros idiomas